SS-31 elamipretide research: from cardiolipin binding to FDA approval in 2025.

In September 2025, SS-31 (elamipretide) became an FDA-approved drug. The agency cleared Forzinity™ for Barth syndrome, a rare mitochondrial disease. That makes it the third FDA-approved peptide we cover here.

Here's why elamipretide matters. Most peptides we cover never make it through clinical trials. SS-31 did. It went through multiple Phase III studies, failed its first big trial, found a responder subgroup, and finally won approval for a rare disease.

That's a rare arc in this field. And it's the appropriate context for evaluating the “SS-31 for athletic performance” marketing circulating online. The approved drug treats one specific genetic disease. Grey-market sourcing is a separate matter.

What is SS-31 doing in the mitochondrion?

SS-31 is tiny. Just four amino acids and a molecular weight of ~640 g/mol. The sequence is D-Arg-Dmt-Lys-Phe-NH₂, and two structural quirks explain how it works.

First, the molecule uses D-amino acids and methylated tyrosine. That makes it resistant to the enzymes (called proteases) that normally chew up peptides in the bloodstream. SS-31 survives long enough to reach its target.

Second, it carries an alternating charge pattern that lets it cross cell membranes and concentrate inside mitochondria. Once there, it binds a specific lipid called cardiolipin.

So what's cardiolipin? It's the signature lipid of healthy mitochondria — the scaffolding that holds the energy-producing machinery in place. When cells are stressed by aging, disease, or genetic defects, cardiolipin becomes damaged. The scaffolding collapses. ATP production drops. Free radicals climb.

A 2025 review in the International Journal of Molecular Sciences by Tung and colleagues (Tung et al., 2025) lays this out clearly. SS-31 binds cardiolipin, stabilizes the scaffolding, and restores energy output. It's the cleanest molecular story we've seen for any peptide in this Research Library.

The Stealth BioTherapeutics development story.

SS-31's journey took over a decade. Stealth originally called it MTP-131 and tested it across four conditions: heart failure, primary mitochondrial myopathy, Barth syndrome, and dry age-related macular degeneration.

Three of those programs are worth a closer look. They show how drug development really works.

MMPOWER-3: the trial that failed

MMPOWER-3 was a Phase III trial in primary mitochondrial myopathy. Adults with genetic mitochondrial disease received either elamipretide 40 mg/day or placebo for 24 weeks. The goal was to improve walking distance and reduce fatigue.

It missed both targets (Karaa et al., 2023). For most drug programs, that's the end.

But Stealth dug deeper. A pre-specified subgroup analysis (Karaa et al., 2024) found that study participants with one type of genetic defect responded, while those with a different mutation type did not.

The responders had “mtDNA replisome” mutations (POLG and TWNK genes). They walked 25.2 m farther vs. 2.0 m on placebo. The subset with chronic eye-muscle weakness did even better at 37.3 m vs. -8.0 m (p=0.0024).

That is the canonical example of how a negative Phase III trial can generate a focused follow-up hypothesis. The NuPOWER Phase III is now testing the responder hypothesis in those specific subject populations.

TAZPOWER: the trial that worked

TAZPOWER ran in Barth syndrome, a rare genetic disease caused by mutations in the TAZ gene. The 28-week trial led to a 168-week open-label extension. Of 10 study participants who entered the extension, 8 reached week 168.

The results (TAZPOWER OLE, 2024) showed lasting improvements in walking distance, fatigue, muscle strength, heart function, and cardiolipin biomarkers.

This is the dataset that won FDA approval. The cohort is tiny because Barth syndrome itself is rare. But the mechanism match is unusually direct: SS-31 binds cardiolipin, and Barth syndrome is a cardiolipin-remodeling disease.

SS-31

Tetrapeptide 4 aa Cardiolipin-binding

The same mitochondria-targeting tetrapeptide cited across the Stealth BioTherapeutics Phase III trials in this review. Lab-verified identity and purity for in-vitro cardiolipin and mitochondrial-function assays.

View SS-31

September 2025: the FDA accelerated approval.

In September 2025, the FDA granted accelerated approval to Forzinity™ for improving muscle strength in Barth syndrome patients weighing 30 kg or more. It's the third FDA-approved peptide we cover, after tesamorelin and bremelanotide. And it's the first approved treatment for Barth syndrome ever.

The Shirley 2025 review in Drugs (Shirley, 2025) walks through the regulatory history. The approval rests on TAZPOWER plus the 168-week extension, with supporting biomarker data.

What does “accelerated approval” mean? The FDA can approve a drug based on a surrogate endpoint (like walking distance) that's likely to predict real clinical benefit. The catch: Stealth must run confirmatory trials after launch. If those trials don't pan out, the FDA can pull the drug.

What Barth syndrome is — and why elamipretide fits.

Barth syndrome is the textbook case for a mitochondrial peptide. Mutations in the TAZ gene break the enzyme that finishes building cardiolipin. The result: malformed cardiolipin, collapsed mitochondrial structure, weak heart muscle, weak skeletal muscle, and low white blood cell counts.

It's an X-linked disease, so it almost always affects boys. Symptoms usually appear in infancy. Without treatment, kids historically didn't live long. Better cardiac care extended survival, but nothing addressed the underlying mitochondrial defect.

The disease is rare: about 1 in 300,000-400,000 live male births. Before Forzinity, treatment meant managing symptoms. Nothing more.

SS-31 doesn't fix the broken TAZ gene. It binds the malformed cardiolipin that the broken enzyme produces. By stabilizing what's there, it preserves enough mitochondrial function to drive measurable strength gains. That's what TAZPOWER showed.

The aging study that didn't move biological age.

A 2025 paper in Aging Cell (Mitchell et al., 2025) tested SS-31 in aged mice for 8 weeks. The peptide reduced frailty. It improved cardiac function. It boosted skeletal muscle endurance.

But it didn't move the molecular clocks. DNA methylation age and transcriptomic age both stayed put.

Read that result two ways. First, it's a reality check on “biological age reversal” marketing. Functional improvements are not the same as turning back a methylation clock. Second, it raises a fair question: are those molecular clocks even the right way to measure aging interventions? Maybe what matters is whether the animal lives better, not whether a software readout drops by a year.

Where this falls short: grey-market SS-31 vs prescription Forzinity.

The marketing positioning of “SS-31” as a longevity or performance peptide runs well past the supportive evidence. The Phase III trials targeted rare diseases with specific genetic profiles. None of that data transfers to healthy adults seeking better workouts.

Grey-market “SS-31” sourced from research-chemical vendors is not equivalent to prescription Forzinity. The quality control, dosing specifications, and clinical context all differ.

For genuine mitochondrial-disease indications, Stealth BioTherapeutics has multiple Phase III studies in active enrollment as of mid-2026; clinical trial enrollment represents the appropriate pathway for investigated therapeutic use.

SS-31

100 mg ≥99% pure Lyophilized

D-Arg-Dmt-Lys-Phe-NH₂ · mitochondria-targeting tetrapeptide. The same reference compound used across the cited preclinical and Phase III studies. COA available with each lot.

Learn more

The safety profile.

Stealth has dosed over 3,500 subjects across the elamipretide program. That's a large database by peptide standards. The most common side effect is injection-site reactions, which is normal for subcutaneous shots. No safety signal has triggered a regulatory hold.

The 168-week TAZPOWER extension supports long-term safety past three years of daily dosing. We should note the limits, though. Cohort sizes for any single indication are small compared with cardiology or cancer trials. Post-marketing surveillance is where the real-world profile will firm up over the next few years.

Clinical and research considerations for elamipretide.

The published literature and regulatory documentation highlight several key parameters for evaluating Forzinity in a clinical or research context:

• Confirmed TAZ gene mutation: Forzinity's approved label is specific to Barth syndrome, a TAZ-linked cardiolipin-remodeling disease.
• Weight threshold (≥30 kg): The approved indication covers patients meeting this threshold; smaller pediatric patients are outside the approved population.
• Access pathway: Specialty pharmacy with insurance pre-authorization. Formal health-economic assessments were not yet published as of mid-2026.
• Off-label PMM use: The NuPOWER Phase III is prospectively testing the MMPOWER-3 responder hypothesis in mtDNA-maintenance disorders; trial enrollment is the evidenced pathway for PMM investigation.
• Mechanism matching for other indications: SS-31 acts through cardiolipin binding. Investigational use in conditions not involving cardiolipin damage lacks a direct mechanistic rationale based on current data.

Where SS-31 goes from here.

Accelerated approval comes with strings attached. Stealth has to run confirmatory trials. So the Forzinity picture will keep evolving through 2028.

The active Phase III programs will report out over the next two years: NuPOWER in PMM, ReCLAIM in dry AMD, and PROGRESS-HF in heart failure. Those results will tell us how broadly the cardiolipin-stabilization mechanism translates beyond Barth syndrome.

For the peptide field overall, SS-31 is the clearest example we have of what real clinical translation looks like. Mechanism work, Phase III trials, a primary endpoint failure handled honestly, a follow-up trial designed from the data, FDA approval through the right pathway. That's the model. The grey-market “peptide as longevity supplement” story isn't.